The natural history of, and risk factors for, progressive chronic kidney disease (CKD): the Renal Impairment in Secondary care (RIISC) study; rationale and protocol
about
Serum endotrophin, a type VI collagen cleavage product, is associated with increased mortality in chronic kidney diseaseAssociation between periodontitis and mortality in stages 3-5 chronic kidney disease: NHANES III and linked mortality study.Endothelial nitric oxide synthase single nucleotide polymorphism and left ventricular function in early chronic kidney disease.Allopurinol is an independent determinant of improved arterial stiffness in chronic kidney disease: a cross-sectional study.Health-Related Quality of Life Impacts Mortality but Not Progression to End-Stage Renal Disease in Pre-Dialysis Chronic Kidney Disease: A Prospective Observational StudyMeasurement properties of patient-reported outcome measures (PROMs) used in adult patients with chronic kidney disease: a systematic review protocol.Caveolin-1 single-nucleotide polymorphism and arterial stiffness in non-dialysis chronic kidney disease.Serum tryptase concentration and progression to end-stage renal disease.The periodontal health component of the Renal Impairment In Secondary Care (RIISC) cohort study: a description of the rationale, methodology and initial baseline results.INfluence of Successful Periodontal Intervention in REnal Disease (INSPIRED): study protocol for a randomised controlled pilot clinical trial.Urinary endotrophin predicts disease progression in patients with chronic kidney disease.Using Patient-Reported Outcome Measures (PROMs) to promote quality of care and safety in the management of patients with Advanced Chronic Kidney disease (PRO-trACK project): a mixed-methods project protocol.Humoral immunity to memory antigens and pathogens is maintained in patients with chronic kidney disease.Association between urinary free light chains and progression to end stage renal disease in chronic kidney disease.
P2860
Q33558001-0AD4E535-F81A-48D4-85DC-302BEF09FC80Q34675029-34227667-F23A-46B9-B697-783468118A91Q35001614-06DA79B9-EB58-403D-9726-BA42036890BCQ35121532-FE5B27AB-6B24-4DA8-B5CE-09C8A25350C7Q36188662-74C833C2-B0D9-45DB-9994-A41BAD59325BQ37356778-C7C60D52-F7E0-45CA-97C2-FBB429399D72Q40471430-C991D724-43A9-49C3-9500-274A1E03C9E9Q40747225-52EA6803-1845-4F0B-BD73-10569737D607Q43887329-8C0EAE70-5274-43F8-AEC5-F9BDA13980E9Q47100087-E6571E7E-7343-49D4-900F-8EEBCD776B8BQ47111536-69848665-7CE6-4E98-ACD0-78873F884FBEQ47138801-80F985B8-DC3A-41E7-BF2B-977D20EB9E8BQ52586069-A5C91500-EA0D-4266-8CBC-9C29D345CED6Q55164205-D723BCA7-5E9E-4ABB-B759-76FDAA8B0DA9
P2860
The natural history of, and risk factors for, progressive chronic kidney disease (CKD): the Renal Impairment in Secondary care (RIISC) study; rationale and protocol
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
The natural history of, and ri ...... study; rationale and protocol
@en
type
label
The natural history of, and ri ...... study; rationale and protocol
@en
prefLabel
The natural history of, and ri ...... study; rationale and protocol
@en
P2093
P2860
P50
P356
P1433
P1476
The natural history of, and ri ...... study; rationale and protocol
@en
P2093
Iain Chapple
Mark Jesky
Mary Dutton
Okdeep Kaur
Stephanie Stringer
P2860
P356
10.1186/1471-2369-14-95
P577
2013-04-25T00:00:00Z